Detection of *Chlamydia trachomatis* in genital swabs: comparison of commercial and in house amplification methods with culture

Richard M Shattock, Craig Patrizio, Peter Simmonds, Sheena Sutherland

**Aims:** To evaluate the sensitivity of the Roche Cobas, Roche Amplicor plate kit, ligase chain reaction (LCR), and an in house polymerase chain reaction (PCR) by titration of purified elementary bodies (EB) and also to test 245 urethral and endocervical specimens for *Chlamydia trachomatis* by the four assays as well as conventional culture.

**Study design:** EB titrations were run in duplicate in each commercial assay and six times in the in house PCR. Clinical samples were aliquoted and tested by each assay and were considered positive if *C trachomatis* was detected by two or more separate tests or if the sample was either culture or immunofluorescence positive. Major outer membrane protein (MOMP) specific primers were used as a confirmatory assay for the in house PCR.

**Results:** The in house PCR, Roche Cobas Amplicor, LCR, and Amplicor plate kit gave detection limits of approximately 1, 1–2, 2, and 2–4 EBs respectively. By the criteria described above for definition of a *C trachomatis* positive result in clinical samples we identified 23 true positives among the 245 clinical specimens. The in house PCR detected all 23 giving a sensitivity of 100% and a specificity of 98%. The Roche Cobas Amplicor, Roche Amplicor plate kit, and LCR detected 21, 19, and 19 of these respectively giving sensitivities of 87.5%, 82%, and 82% respectively and specificities of 99.5%, 99%, and 100% respectively. The culture gave a sensitivity of 78% and specificity of 100%.

**Conclusion:** All four amplification assays had a greater sensitivity than the culture used routinely in this laboratory. The in house plasmid PCR had the greatest sensitivity and when combined with confirmation by immunofluorescence detected the greatest number of positives. This increased sensitivity is likely to have been achieved by the use of a DNA purification step and of nested primers in the amplification stage and their combined use in routine diagnostic assays for *chlamydia* might increase the frequency of *C trachomatis* detections. However, this assay is much less user friendly than the two semiautomated commercial assays investigated in this study.

(STM Infect 1998;71:289–293)

Keywords: genital swabs; *Chlamydia trachomatis*; amplification methods

**Introduction**

*Chlamydia trachomatis* serovars D-K are the commonest cause of non-gonococcal urethritis in males and mucopurulent cervicitis and urethritis in females. Many patients are asymptomatic and if untreated they will be a risk both to their partners and to themselves. For example ascending infection can occur, and in females can result in pelvic inflammatory disease (PID) causing ectopic pregnancies and infertility. It is therefore desirable to identify chlamydial infections in infected individuals and administer appropriate treatment before further complications arise.

Laboratory diagnosis of *C trachomatis* was originally based on the culture of urethral and endocervical swabs. More recently, attempts have been made to develop more rapid methods, such as the detection of chlamydial antigen by immunological assays. Among these, direct fluorescent antibody assays (DFA) and enzyme linked immunosorbent assay (ELISA) using monoclonal antibodies directed against chlamydial antigens have become widely used. These show sensitivities similar to that of culture, although precise comparisons are influenced by the methods of sample collection, transport, and storage.

Alternatives to immunological detection are methods based upon the amplification of bacterial nucleic acid sequences. Two techniques developed for the detection of *C trachomatis* are the ligase chain reaction (LCR, Abbott) and Roche Cobas Amplicor. Both methods amplify sequences from a cryptic plasmid present within bacterial cells at copy numbers of 7–10. These methods may therefore be more sensitive than amplification of single gene sequences from the bacterial genome such as those coding for the major outer membrane protein (MOMP). The Roche Cobas Amplicor is an automated system of the conventional Roche Amplicor polymerase chain reaction (PCR) plate kit. Like the LCR, the Roche Cobas has a manual sample processing but allows automated amplification and detection as well as result reporting.

Our study involved the comparison of Roche Cobas Amplicor, Roche Amplicor plate kit, Abbott LCR, in house PCR, and culture on swabs collected routinely over 2 weeks from 245 patients attending a single genitourinary medicine clinic (GUM) and a single local general practice.
Materials and methods

STUDY POPULATION
The specimens used in the study were consecutive swabs sent in sucrose phosphate (2SP) transport medium for routine culture (251) over 10 working days with the exception of six samples. Three of the excluded samples were conjunctival swabs, one was a rectal swab, and two had insufficient 2SP for all the tests to be performed. The remaining 245 were collected from 120 males and 125 females. Urethral swabs numbered 123 (120 male, three female), endocervical swabs 121, and one female swab was site unknown. The GUM patients comprised 138 patients attending for the first time, 66 previous attenders with a new episode of illness, and 20 previous attenders returning for follow-up of a recent episode. None of the general practitioner patients was on follow-up visits.

COLLECTION OF SAMPLES
To avoid the swab sample variation that can occur when multiple swabs are taken, only one swab was submitted for each patient. The swab sent for chlamydia culture was the second swab taken, the first swab being sent for bacteriology. The volume of 2SP was not increased so that our routine culture sensitivity would not be compromised and to ensure that our service to the patients remained as normal. The swabs were received in approximately 1.2 ml of 2SP transport medium. Specimens were vortexed for 1 minute, 500 µl of the specimen was cultured, and four aliquots of 100 µl were used for each of the other tests. The remaining specimen (approximately 300 µl) was stored for immunofluorescence (IF) if required.

The LCR (Abbott) required resuspension of the sample in manufacturer's diluent as 2SP is unsuitable for this test. Aliquots tested by this method were prepared according to the manufacturer's instructions for testing urine samples and so were centrifuged at 15 000 rpm for 10 minutes, the supernatant discarded, and pellets stored at −70°C. Pellets were resuspended in 100 µl of the manufacturer's urine resuspension buffer before testing.

APPLICATION OF METHODS

ELEMENTARY BODY TITRATIONS
Elementary bodies (EBs) were purified and dilutions made in phosphate buffered saline (PBS). Dilutions containing 1000, 100, 10, 0.1 EBs in 100 µl were run in duplicate on each assay except the in house PCR which was repeated six times. The detection limit was calculated by taking the dilution factor into account during sample processing and assuming 10 plasmid copies per EB. All assays used 100 µl volumes. DNA for the in house PCR was eluted in 50 µl of which 5 µl was used in the PCR (1/10). The Roche Cobas and Roche Amplicor plate kit used 50 µl of prepared sample from a total volume of 400 µl (1/8). The LCx used all of the 100 µl in the amplification.

CHLAMYDIA CULTURE
Volumes of 500 µl of each sample were inoculated with centrifugation at 37°C for 1 hour onto monolayers of McCoy cells in the presence of cycloheximide and incubated for 72 hours at 37°C. Cells were stained with iodine and inspected microscopically for the presence of glycogen containing inclusions.8

IMMUNOFLUORESCENCE
Slides were prepared by cytocentrifuge method using 150 µl of sample and fixed in methanol. PathoDX MOMP specific antibody was used for EB detection.

IN HOUSE PCR
DNA was extracted using the Qiamp viral RNA extraction kit. Nested primers (table 1) were used to amplify a 108 bp fragment of the cryptic plasmid. The amplicon was detected by ethidium bromide staining after electrophoresis through a 2% agarose gel. A second assay using nested primers to amplify a 94 bp fragment of the MOMP gene (table 1) was performed on all samples which gave a positive reaction with the plasmid assay.

ROCHE AMPICOR PLATE KIT AND ROCHE COBAS AMPLICOR
All Roche assays were carried out according to the manufacturer's instructions. During the study Roche changed the sample preparation method for the plate kit so that the newer kit was used for the EB dilution series and the older kit for the 245 specimens.

ABBOTT LIGASE CHAIN REACTION
Pelleted samples, resuspended in LCx urine resuspension buffer, were tested according to the manufacturer's instructions.

DEFINITION OF A POSITIVE SAMPLE
All 245 clinical samples were tested by culture, in house PCR, and Roche Cobas Amplicor, Roche Amplicor plate kit, and Abbott LCR. Immunofluorescence was carried out on discrepant results as a confirmatory test and all plasmid positive samples were retested with MOMP primers. Samples were considered positive if (1) culture positive, (2) culture negative but positive by IF, or (3) positive in two or more of any other assays.

Results
By the criteria defined in the methods section a total of 23 of the 245 (9.4%) clinical specimens were positive for C trachomatis. Eleven (9%) were male samples and 12 (9.5%) were female samples.

CLINICAL FEATURES
Patients could be classified as asymptomatic, symptomatic possibly chlamydia related (SPC), and symptomatic but unrelated to chlamydia
(UC). There were 104 asymptomatic patients of whom 11 had returned for test of cure investigations and five were known contacts of chlamydia positive partners. Eighty three patients had symptoms unrelated to chlamydia and 58 had symptoms possibly related to chlamydia. The positivity rate in the three categories was (a) 10%, (b) 2.4%, and (c) 19%. Of the 30 patients with NSGI, nine (30%) were positive and two of the 27 (7.4%) with vaginal discharge; one of these also had genital warts. Ten (10%) of the asymptomatics were positive; two of these were tests of cure—one male, one female—and two were female contacts of known positives. The other asymptomatic patients were one male and five females. The remaining two positives were detected in two female patients with other STDs—one with herpes simplex infection the other with genital warts.

ASSAY RESULTS
Using the Roche Cobas Amplicor, 22 samples were positive, one of which was repeat positive but IF negative (table 2, case 5: indeterminate). The Roche plate kit detected 21 positives, 18 of which were culture positive while two of the remaining three samples were negative on repeat testing (table 2, cases 6 and 7). The other Roche positive was LCR positive and in house PCR positive but IF negative. There were also two Roche equivocals, one was negative on repeat testing and the second repeated equivocal (table 2, case 12). The LCR detected 19 positives and one equivocal which was IF negative but Cobas and in house PCR positive (table 2, case 12). There were no LCR false positives.

In house PCR gave a total of 27 positives using the plasmid primers. There were three presumed false positives which were negative by PCR using MOMP primers and negative upon repeat testing by the plasmid primers (table 2, cases 2, 3, and 4). One specimen was repeatedly positive using plasmid primers, MOMP assay negative and IF negative (table 2, case 1: indeterminate). By the criteria for positivity described above, these samples have been scored as false positives, although the latter sample may contain chlamydial DNA at a low level. Two specimens were repeatedly positive by plasmid primers, negative by MOMP primers, but positive by IF (cases 8 and 9). There was also one specimen positive by plasmid primers, culture positive, and IF positive with four EBs but was negative by all other methods (case 10).

Table 2 (A) Presumed false positives

<table>
<thead>
<tr>
<th>ID</th>
<th>Sex</th>
<th>Spec Type</th>
<th>Diag/Hist</th>
<th>PPCR†</th>
<th>MPCR†</th>
<th>Culture</th>
<th>LCR</th>
<th>Cobas</th>
<th>Roche</th>
<th>IF</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M†</td>
<td>ASYM</td>
<td></td>
<td>(+/-)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td>Ind†</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>ASYM</td>
<td></td>
<td>(+/-)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>F*</td>
<td>BC† rash</td>
<td></td>
<td>(+/-)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>BC</td>
<td>warts</td>
<td>(+/-)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>TOC</td>
<td></td>
<td>(+/-)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>TOC</td>
<td></td>
<td>(+/-)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>BC</td>
<td>VDIS</td>
<td>(+/-)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

†All positives with plasmid primers were retested using MOMP primers. A negative by MOMP primers was considered a false plasmid positive. IF results were not taken into account.

Table 3 Comparison of methods with confirmed results on sensitivity and specificity

<table>
<thead>
<tr>
<th>Test and result</th>
<th>Confirmed results</th>
<th>Plasmid PCR only*</th>
<th>Plasmid and MOMP PCR†</th>
<th>Roche Cobas</th>
<th>Roche plate kit</th>
<th>Culture</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive</td>
<td>Negative</td>
<td>Sensitivity (%)</td>
<td>Specificity (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasmid PCR only*</td>
<td>23</td>
<td>4</td>
<td>100</td>
<td>98</td>
<td></td>
<td></td>
</tr>
<tr>
<td>negative</td>
<td>0</td>
<td>218</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasmid and MOMP PCR†</td>
<td>20</td>
<td>0</td>
<td>86</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>positive</td>
<td>3</td>
<td>222</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roche Cobas</td>
<td>21</td>
<td>1</td>
<td>87.5</td>
<td>99.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>positive</td>
<td>2</td>
<td>221</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roche plate kit positive</td>
<td>19</td>
<td>2</td>
<td>82</td>
<td>99</td>
<td></td>
<td></td>
</tr>
<tr>
<td>negative</td>
<td>4</td>
<td>220</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCR positive</td>
<td>19</td>
<td>0</td>
<td>82</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>negative</td>
<td>4</td>
<td>222</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Culture positive</td>
<td>18</td>
<td>0</td>
<td>78</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>negative</td>
<td>5</td>
<td>222</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Sensitivities and specificities calculated if plasmid results only are taken.
†All positives with plasmid primers were retested using MOMP primers. A negative by MOMP primers was considered a false plasmid positive. IF results were not taken into account.

Table 2 (B) Presumed false negatives

<table>
<thead>
<tr>
<th>ID</th>
<th>Sex</th>
<th>Spec Type</th>
<th>Diag/Hist</th>
<th>PPCR†</th>
<th>MPCR†</th>
<th>Culture</th>
<th>LCR</th>
<th>Cobas</th>
<th>Roche</th>
<th>IF</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>M</td>
<td>ASYM/Partner NSGI††</td>
<td>(+/-)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>2EBs</td>
<td>Low level+</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>TOC</td>
<td></td>
<td>(+/-)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3EBs</td>
<td>&quot;</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>BC</td>
<td>VDIS</td>
<td>(+/-)</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>4EBs</td>
<td>&quot;</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>NSGI</td>
<td></td>
<td>(+/-)</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>6EBs</td>
<td>Low level+</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>BC</td>
<td>ASYM</td>
<td>(+/-)</td>
<td>-</td>
<td>-</td>
<td>(eq)††</td>
<td>(eq)−</td>
<td>Roche false+</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

†Sensitivities and specificities calculated if plasmid resultsonlyaretaken.
and plasmid numbers rather than EBs are used the true endpoints may be 1, 1–2, 2–3, and 20 plasmid copies for the in house PCR, Roche Cobas Amplicor, Roche Amplicor plate kit (improved version), and LCR respectively.

A number of discrepant results were observed in this study. Initial in house PCR screening with plasmid primers gave 27 positive results, 23 of which were confirmed positive. Three unrepeatable positives with the plasmid primers were probably due to contamination during the PCR in spite of strict adherence to the rules for PCR performance. A sample from one asymptomatic patient who was repeatedly positive by the plasmid primers may have contained chlamydial DNA, but unfortunately no follow up sample was available to confirm this.

A number of workers have shown that patients can be PCR positive, even 4 weeks after treatment, while experimental work in monkeys has shown that PCR can detect chlamydia up to 5 weeks after samples become culture negative. In this study 10 specimens were from patients who had been diagnosed as positive and had returned for a check following treatment; two of these were positive; one by all assays and one by in house PCR and IF.

The Roche Cobas Amplicor gave positive results for 21 samples compared with 19 on the Roche plate kit. Since the clinical samples reported here were tested Roche have modified their plate kit. The modified version, used in the dilution series, appears to be closer in sensitivity to the Cobas.

The LCR gave no false positive results but failed to detect one sample positive by culture and two samples positive by in house PCR and IF. An additional sample which was in house PCR and Roche Cobas positive gave an LCR result just below the cut off. These false negatives could not be explained by an absence of the 7.5 kb cryptic plasmid in that the in house PCR primers used this target sequence for amplification. It is possible that a mutation could have prevented hybridisation of the probes to the target sequence, or LCR inhibitors may have been present. The presence of inhibitors for urines has been discussed previously for LCR in which prolonged storage and freeze thawing reduced the effects of these inhibitors. Since two of these missed positives were male urethral swabs the possibility of inhibitors being present cannot be ruled out. However, a more likely explanation was that the number of elementary bodies was very low in these specimens. The culture system used 500 µl of specimen yet two of these miss positives were not have contained any or very few elementary bodies even though before aliquoting, samples were vortexed for 1 minute to ensure homogeneity. Low levels of plasmid DNA may be detected more efficiently by nested PCR, which increases theoretical sensitivities for single copies of target sequence.

Previous work has suggested that the sensitivities of Roche PCR plate kit and Abbott LCR are equivalent and that the cut off level of both assays is 2–4 elementary bodies, perhaps

Discussion
A number of previous studies have compared various commercial assays, culture systems, in house PCRs, and IF for C trachomatis, although few have evaluated more than two assays using a common set of specimens. This study was designed to carry out a comprehensive analysis of currently available diagnostic assays and used a variety of criteria to define positive samples in the calculation of the sensitivity and specificity of each. The study also included an EB dilution series which was harvested at 72 hours to ensure inclusions had released EBs and reticulate bodies had reorganised into EBs. No reticulate bodies were seen during total EB counts.

The results given in table 4 for the plasmid based assays may show differences that were simply due to chance since in the very dilute samples the EB distribution would be determined according to the Poisson distribution. This difficulty could have been partially overcome if, for example, 25 replicates of each dilution had been tested in each assay but such an exercise was well beyond our budget. However, it is also possible that the differences may be greater than shown. If the volumes used in each assay are allowed for in the calculation

![Comparison of sample reading/cut off ratios between commercial assays for 245 clinical specimens.](image-url)
explaining their inability to detect a culture positive sample with a low level of elementary bodies detected by IF. In automating the system Roche have been able to increase sensitivity and specificity of their assay.

The in house PCR was 9% more sensitive than the Roche amplification system with a small loss in specificity (98%). Processing time was reduced using QIamp viral RNA extraction columns with a vacuum manifold. This increased sample throughput considerably when compared with conventional phenol/chloroform extraction methods. The extraction method allows the processing of 48 samples within an hour and positive results could be confirmed within 48 hours. If the in house PCR was used for routine diagnosis, all plasmid positives would be confirmed with MOMP and/or IF before reporting to the clinician. The plasmid primers were more sensitive than the MOMP primers as shown by the two plasmid/IF positive but MOMP primer negative samples. One sample was repeatedly plasmid positive but MOMP and IF negative which might indicate that some samples may be unconfirmable; these would have to be reported as indeterminate and a repeat sample supplied.

The semi-automated commercial assays had distinct advantages over the in house PCR from the technician’s point of view in that the preparation step before amplification was much simpler and the hands on time thereafter was much less. When large numbers of samples have to be processed every day the risk of operator error increases and this risk was greatest with the in house assay. A speedier result was the other main advantage of the commercial assays. The advantages of the in house assay in addition to greater sensitivity were cost and the fact that the result would be confirmed before reporting. However the royalty payment to Roche would decrease cost savings advantages.

The demonstrated lower sensitivity of culture means that it can no longer be regarded as the gold standard for C. trachomatis. In addition, variations in sensitivity from centre to centre, the need for well taken specimens transported rapidly in cold conditions, and its unsatisfactory detection rate in urines all make it more fallible than molecular methods. The additional positives detected by in house PCR increased the detection rate from 8% (as previously reported in this laboratory) to 9.5%. These increased detection rates are also seen with the commercial assays. An expanded gold standard should include the use of nucleic acid amplification technologies, either in house PCRs or commercially available tests, because of their higher sensitivities.

We would like to thank Azra Sharif-Quayum for expert technical assistance in the routine culture, Roche Diagnostics for the supply of Amplicor PCR kits and Abbott for the use of the LCA system.

Contributors: RMS and CP did the laboratory bench work. PS and SS were responsible for the design and interpretation and for obtaining clinical details.

Further details of the materials and methods used may be obtained from the journal offices.